Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Health and Medical Research Fund | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
This study aims to assess the effect of puerarin supplementation on cardiovascular disease risk factors in men.
Objectives: To assess the effect of puerarin supplementation on cardiovascular disease risk factors in men.
Study design: A randomized, double-blind, placebo-controlled, 2-way crossover trial of 12-week puerarin supplementation.
Study subjects: 234 Hong Kong Chinese men aged 18-50 years without a history of cardiovascular disease.
Intervention: After assessing eligibility, all participants will be randomized to take a puerarin supplement in granules (90.2 mg daily) or a placebo, followed by a 4-week wash-out period, after which participants will be crossed over to the other intervention.
Primary outcomes: Lipid profile (total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides).
Secondary outcomes: Cardiovascular disease risk factors, such as blood pressure and fasting glucose, as well as some potential mediating pathways, such as testosterone.
Methods: An intention to treat analysis will be used, assuming no changes in baseline value for missing follow up values. Differences in outcomes between supplementation and placebo within participants will be compared using a paired t-test, after checking for the possibility of a carryover effect.
Expected results: The short-term effect of puerarin on cardiovascular disease risk factors in men will be obtained so as to confirm or refute previous trials usually with small sample sizes that suggest puerarin may improve lipid profile and reduce testosterone. The findings will also add evidence about the effects of puerarin on other potentially relevant risk factors, such as blood pressure, fasting glucose and testosterone, as well as some related biomarkers.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Puerarin | Experimental | Puerarin (90.2 mg daily) in granules |
|
| Placebo | Placebo Comparator | Placebo in granules |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Puerarin | Drug | Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in total cholesterol | Mean difference in total cholesterol (mmol/L) | Baseline, 12 weeks, 16 weeks and 28 weeks |
| Change in low density lipoprotein (LDL) cholesterol | Mean difference in LDL cholesterol (mmol/L) | Baseline, 12 weeks, 16 weeks and 28 weeks |
| Change in high density lipoprotein (HDL) cholesterol | Mean difference in HDL cholesterol (mmol/L) | Baseline, 12 weeks, 16 weeks and 28 weeks |
| Change in triglycerides | Mean difference in triglycerides (mmol/L) | Baseline, 12 weeks, 16 weeks and 28 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in blood pressure | Mean difference in systolic and diastolic blood pressure (mmHg) | Baseline, 12 weeks, 16 weeks and 28 weeks |
| Change in fasting glucose | Mean difference in fasting glucose (mmol/L), with log transformation if appropriate |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gabriel M Leung, M.D. | The University of Hong Kong | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Hong Kong | Hong Kong | China |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Aug 11, 2022 | |
| Reset | Jul 6, 2023 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Aug 11, 2022 | Jul 6, 2023 |
| ID | Term |
|---|---|
| C033607 | puerarin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks |
|
| Baseline, 12 weeks, 16 weeks and 28 weeks |
| Change in testosterone | Mean difference in testosterone (nmol/L), with log transformation if appropriate | Baseline, 12 weeks, 16 weeks and 28 weeks |